Loading…
Fulgent Genetics, Inc. is projected to rise to $26.07 by 2027, a +27% move from its current price of $20.55. FLGT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $20.16 | $20.56 | $20.97 | +0.04% |
| Jul 15 | $20.00 | $20.57 | $21.15 | +0.09% |
| Jul 16 | $19.88 | $20.58 | $21.30 | +0.13% |
| Jul 17 | $19.79 | $20.59 | $21.42 | +0.17% |
| Jul 18 | $19.70 | $20.59 | $21.53 | +0.22% |
| Jul 19 | $19.63 | $20.60 | $21.63 | +0.26% |
| Jul 20 | $19.56 | $20.61 | $21.72 | +0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.56 | $20.61 | $21.72 | +0.30% |
| Week 2 | $19.20 | $20.68 | $22.27 | +0.61% |
| Week 3 | $18.94 | $20.74 | $22.71 | +0.92% |
| Week 4 | $18.73 | $20.80 | $23.10 | +1.22% |
| Week 5 | $18.56 | $20.86 | $23.46 | +1.53% |
| Week 6 | $18.41 | $20.93 | $23.79 | +1.84% |
| Week 7 | $18.27 | $20.99 | $24.11 | +2.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients.
Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Fulgent Genetics, Inc. (FLGT) is a healthcare company focused on clinical diagnostic and therapeutic development solutions. The asset is currently priced at $20.82 and has a market cap of $591.3M, with a market rank of 2944.
The current fundamentals place the stock in a mid-cap healthcare niche with a broad service offering across diagnostics and therapeutic development.
A major floor 32.9% below — a decisive break under it would weaken the trend.
The nearest floor, 13.9% below — buyers have tended to step in here.
The nearest ceiling, 4.1% above — a clean break opens room to run.
A major ceiling 14.7% above — clearing it would confirm fresh momentum.
Key FLGT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FLGT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.89 | Sell | $20.72 | Sell |
| MA 10 | $20.71 | Sell | $20.47 | Buy |
| MA 20 | $19.56 | Buy | $19.82 | Buy |
| MA 50 | $17.90 | Buy | $18.70 | Buy |
| MA 100 | $17.34 | Buy | $18.90 | Buy |
| MA 200 | $21.57 | Sell | $19.88 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.84 | Neutral |
| Stoch RSI (14) | 45.26 | Neutral |
| CCI (20) | 57.23 | Neutral |
| Williams %R (14) | -23.66 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 13.04 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 76.34 | Neutral |
| TRIX (15) | 0.65 | Buy |
| Awesome (5,34) | 1.86 | Buy |
| Ultimate (7,14,28) | 59.07 | Neutral |
| Momentum (10) | 1.11 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 20.77 | Sell |
| ADX (14) | 27.73 | Buy |
| ATR (14) | 0.36 | Info |
In the near term, the 30-day technical picture shows bullish sentiment with RSI14 at 70. The stock trades above the 50-day simple moving average of $17.30 and near the 200-day simple moving average of $21.61. The identified support level stands at $15.95 and the resistance at $20.82. The thirty-day price range runs from a low of $18.03 to a high of $24.04.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.79 | $20.55 | $27.85 | 0% | Neutral | |
| $21.29 | $26.07 | $33.43 | +27% | Bullish | |
| $26.36 | $32.93 | $43.42 | +60% | Bullish | |
| $31.88 | $40.47 | $54.56 | +97% | Bullish | |
| $40.05 | $51.57 | $70.83 | +151% | Bullish | |
| $45.54 | $59.40 | $82.92 | +189% | Bullish | |
| $48.14 | $63.53 | $90.02 | +209% | Bullish | |
| $54.94 | $73.32 | $105.28 | +257% | Bullish | |
| $59.57 | $80.34 | $116.81 | +291% | Bullish | |
| $67.99 | $92.63 | $136.22 | +351% | Bullish | |
| $105.87 | $150.81 | $232.86 | +634% | Bullish | |
| $237.52 | $364.57 | $604.97 | +16.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $13.79 | $20.55 | $24.90 | +0.00% |
| August 2026 | $18.23 | $21.35 | $25.56 | +3.90% |
| September 2026 | $18.16 | $21.38 | $25.81 | +0.13% |
| October 2026 | $18.69 | $22.11 | $26.87 | +3.40% |
| November 2026 | $19.20 | $22.79 | $27.87 | +3.10% |
| December 2026 | $19.02 | $22.65 | $27.85 | -0.61% |
Click any year to see its month-by-month FLGT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, FLGT is projected to trade between $13.79 and $27.85, averaging $20.55 — a potential gain of 0% from today's $20.55. Price action looks broadly range-bound.
Fulgent Genetics, Inc.'s 2027 outlook centres on $26.07, within a $21.29 to $33.43 range. That is up +27% on the projected 2026 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, FLGT could reach as high as $43.42, with a base case around $32.93 and support toward $26.36 — roughly +60% from $20.55. Momentum favours further upside here.
Expect FLGT to range from $31.88 to $54.56 through 2029. The $40.47 average target implies a +97% move from current prices. That is up +23% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The FLGT price prediction for 2030 points to an average of $51.57 (low $40.05, high $70.83) — a potential gain of +151% on today's $20.55. Momentum favours further upside here.
In 2031, FLGT is projected to trade between $45.54 and $82.92, averaging $59.40 — a potential gain of +189% from today's $20.55. That is up +15% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Fulgent Genetics, Inc.'s 2032 outlook centres on $63.53, within a $48.14 to $90.02 range. That is up +7% on the projected 2031 average. That marks a +209% change versus current levels. Momentum favours further upside here.
By 2033, FLGT could reach as high as $105.28, with a base case around $73.32 and support toward $54.94 — roughly +257% from $20.55. Buyers look set to stay in control over this stretch.
Expect FLGT to range from $59.57 to $116.81 through 2034. The $80.34 average target implies a +291% move from current prices. That is up +10% on the projected 2033 average. Momentum favours further upside here.
The FLGT price prediction for 2035 points to an average of $92.63 (low $67.99, high $136.22) — a potential gain of +351% on today's $20.55. Buyers look set to stay in control over this stretch.
In 2040, FLGT is projected to trade between $105.87 and $232.86, averaging $150.81 — a potential gain of +634% from today's $20.55. That is up +63% on the projected 2035 average. Momentum favours further upside here.
Fulgent Genetics, Inc.'s 2050 outlook centres on $364.57, within a $237.52 to $604.97 range. That is up +142% on the projected 2040 average. That marks a +16.7x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in FLGT today (≈ 48.6618 FLGT) could be worth
$17,740.46
+$16,740.46 (+1674%) by 2050 · US Dollar
Based on the average projected FLGT price of $364.57 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FLGTwould be worth at today's price.
$1,000 invested in FLGT on Jul 10, 2025 (≈ 51.150897 FLGT) would be worth
$1,051.15
+$51.15 (+5.1%) today · 1.05× · US Dollar
Based on a FLGT entry price of $19.55 vs. today's $20.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $20.85 | $985.61 | -1.4% |
| 1 month ago | $18.93 | $1,085.58 | +8.6% |
| 3 months ago | $14.43 | $1,424.12 | +42.4% |
| 6 months ago | $28.16 | $729.76 | -27.0% |
| 1 year ago | $19.55 | $1,051.15 | +5.1% |
| All time (5.0y) ago | $74.87 | $274.48 | -72.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FLGT forecast.
Our base-case forecast reaches $41.00 around 2030.
Implied market cap at $41.00: $1.16B
The multi-year forecast provides a path of growing values and positive returns. For 2026, the expected average price is $20.82 with a min of $13.79 and a max of $28.02, and a neutral sentiment. From 2027 onward, the forecast shows stronger upside with a 2027 avg of $25.83 and 2027 max of $33.48 (ROI 24.1%, bullish).
The trajectory continues with 2028 avg $31.82 (ROI 52.8%), 2029 avg $38.01 (ROI 82.5%), 2030 avg $48.20 (ROI 131.5%), 2031 avg $54.64 (ROI 162.4%), 2032 avg $57.44 (ROI 175.9%), 2033 avg $66.35 (ROI 218.7%), 2034 avg $70.99 (ROI 241%), 2035 avg $80.25 (ROI 285.4%), 2040 avg $127.67 (ROI 513.2%), and 2050 avg $297.41 (ROI 1328.5%), with bullish sentiment through the longer horizon. These figures imply substantial long-term upside while acknowledging the inherent uncertainty of markets and that these are projections, not guarantees.
Tap a question to reveal the answer.
The forecasted 2030 average price is $48.20 with a min of $36.96 and a max of $67.29, and an estimated ROI of 131.5% with bullish sentiment.
Forecasts show a bullish long-term trajectory with rising averages through 2035 and beyond (e.g., 2030 avg $48.20 and 2050 avg $297.41, ROI up to 1328.5%). The 2026 view is neutral at an average of $20.82, indicating mixed near-term outlook amid longer-term upside, and these are estimates, not guarantees.
The forecast maximums show $97.18 in 2033 and $202.17 as a max in 2040, suggesting that surpassing $100 could occur by the 2040 horizon according to the provided projections.
Current price is $20.82. The 30-day range is from $18.03 to $24.04.
Market cap is $591.3M and the rank is 2944.
Fulgent Genetics, Inc. Community Discussion
0Share your Fulgent Genetics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.